Nucana Stock Price, News & Analysis

NuCana plc appoints Bali Muralidhar, M.D., Ph.D. to its Board of Directors, enhancing its leadership team as it advances its ProTide pipeline targeting cancer treatment. This follows a successful $80 million public offering, with significant investment from Abingworth, a prominent life sciences investment firm. The new funding is expected to accelerate the development of ProTides, which include three products currently in clinical trials. Management believes these advancements could significantly improve patient outcomes in oncology.

NuCana plc (NASDAQ: NCNA) reported promising results for its clinical programs at ESMO 2020.

The Phase Ib study of NUC-3373 in advanced colorectal cancer showed its ability to stabilize disease and enhance progression-free survival in heavily pre-treated patients. Moreover, NUC-7738 exhibited anti-cancer activity with a favorable tolerability profile in advanced solid tumors. NuCana aims to replace standard cancer treatments with its ProTide technology, evidenced by these encouraging early results.

NuCana plc has announced a public offering of 15,555,556 American Depositary Shares (ADSs) at $4.50 each, aiming to raise approximately $70 million before expenses. The underwriters also hold a 30-day option for an additional 2,333,333 ADSs. All proceeds from the offering, expected to close around September 21, 2020, will enhance NuCana’s pipeline, which includes treatments for cancer using their ProTide technology. The company emphasizes its commitment to improving therapeutic outcomes for patients with cancer.

NuCana is initiating an underwritten public offering of its American Depositary Shares (ADSs), each representing one ordinary share. The underwriters have a 30-day option to purchase an additional 15% of the ADSs at the public offering price. The offering is part of a previously declared effective registration statement and is subject to market conditions. No assurance can be provided regarding the completion or terms of the offering. Jefferies, Cowen, William Blair, and Truist Securities are the joint book-running managers.

NuCana plc (NASDAQ: NCNA) announced its financial results for Q2 2020, reporting a net loss of £6.1 million compared to £4.5 million in Q2 2019. The cash position was stable at £47.8 million. CEO Hugh Griffith highlighted the company's ongoing clinical trials, including the Phase III study of Acelarin in biliary tract cancer, and advancements in NUC-3373 and NUC-7738. Positive data presented at the American Association for Cancer Research indicated the ProTides' potential to enhance immune checkpoint inhibitors. A cash runway is expected to last into Q4 2021.

NuCana plc (NASDAQ: NCNA) reported Q1 2020 financial results, revealing a net loss of £4.0 million, an improvement from £5.4 million the previous year. As of March 31, 2020, cash and equivalents stood at £47.6 million, down from £52.0 million at the end of 2019. Following a temporary pause in clinical trials due to COVID-19, patient enrollment has resumed. The company expects its cash runway to last until at least Q4 2021, aided by cost-saving measures. Upcoming milestones include continued enrollment in various clinical studies and data reporting for several ProTide therapeutics.

NuCana (NASDAQ: NCNA) has resumed patient enrollment in multiple clinical studies following a temporary pause due to COVID-19. The Phase III trial of Acelarin plus cisplatin for biliary tract cancer (NuTide:121) reopened on May 5, 2020, and new trials for NUC-3373 and NUC-7738 are now also active. CEO Hugh S. Griffith emphasized the importance of advancing cancer treatments amidst the pandemic. The studies are underway in various countries including Australia, Canada, and the UK, highlighting NuCana's commitment to developing innovative cancer therapies.

NuCana plc (NASDAQ:NCNA) announced that two abstracts detailing non-clinical studies on its ProTides, Acelarin (NUC-1031) and NUC-3373, have been selected for presentation at the AACR Annual Meeting 2020 from June 22-24, 2020. Acelarin has shown potential as an immunomodulatory agent, increasing PD-L1 expression and releasing DAMPs in lung cancer cells. Meanwhile, NUC-3373 induces ER stress and DAMP release in colorectal cancer cells. Both candidates may enhance the efficacy of immune checkpoint inhibitors in cancer treatment.

NuCana plc (NASDAQ: NCNA) has resumed patient enrollment in its global Phase III study, NuTide:121, for Acelarin combined with cisplatin in treating biliary tract cancer. Enrollment is re-opened in regions including Australia, Canada, South Korea, Taiwan, Ukraine, and the UK. The ongoing COVID-19 pandemic has impacted global healthcare, making this study's resumption critical for patient treatment. The trial aims to enroll up to 828 patients across about 120 sites worldwide, comparing Acelarin and cisplatin against the standard gemcitabine plus cisplatin regimen.